Clinical Trials Browser

Phase 2 × INDUSTRY × Multiple Myeloma × Clear all

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

Multiple Myeloma

NCT06550895 2026-04-14

MonumenTAL-8

Phase 2 Active not recruiting

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

Phase 2 Active not recruiting

Multiple Myeloma

NCT04634552 2026-04-13

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 2 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT05955508 2026-04-13

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06500884 2026-04-13

Talisman

Phase 2 Recruiting

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07266441 2026-04-13

TRIlogy-3

Phase 2 Recruiting

Multiple Myeloma

NCT02952508 2026-03-18

CLOVER-WaM

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT07284758 2026-03-12

MOMENTUM

Phase 2 Recruiting

Multiple Myeloma

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2 Active not recruiting

46 enrolled 15 charts

Multiple Myeloma

NCT05561751 2026-02-12

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase 2 Completed

Multiple Myeloma

NCT04977024 2026-02-11

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

COVID-19, Leukemia, Lymphoma, Multiple Myeloma

NCT05396885 2026-02-11

iMMagine-1

Phase 2 Active not recruiting

Multiple Myeloma

NCT05014412 2026-02-10

MagnetisMM-9

Phase 2 Completed

86 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT06297226 2026-02-10

QUINTESSENTIAL

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT05172596 2026-01-13

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05704049 2025-12-29

IZALCO

Phase 2 Active not recruiting

Multiple Myeloma

NCT03758417 2025-12-17

CARTIFAN-1

Phase 2 Terminated

Multiple Myeloma

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 2 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Not yet recruiting

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

Phase 2 Active not recruiting

Multiple Myeloma

NCT05064358 2025-10-07

DREAMM 14

Phase 2 Active not recruiting

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Phase 2 Completed

221 enrolled 61 charts 3 FDA

Multiple Myeloma

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms

NCT03628612 2025-08-07

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

Phase 2 Enrolling by invitation

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, T-Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01946477 2025-06-06

POM MM 014

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT03361748 2025-05-23

KarMMa

Phase 2 Completed

149 enrolled 29 charts 1 FDA

Multiple Myeloma, Recurrence

NCT04176380 2025-05-15

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 5 FDA

Multiple Myeloma

NCT02316106 2025-04-27

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Phase 2 Completed

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06566547 2025-04-27

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05347485 2025-04-25

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Phase 2 Completed

86 enrolled 19 charts

Multiple Myeloma

NCT03860038 2025-04-24

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma

NCT03871829 2025-03-30

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Phase 2 Terminated

88 enrolled 21 charts

Multiple Myeloma

NCT02924272 2025-03-12

Ixazomib Rollover Study

Phase 2 Completed

32 enrolled 13 charts

LymphoidPlasma cell

Amyloidosis, Lymphoma, Multiple Myeloma

NCT02874742 2025-02-04

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

224 enrolled 19 charts

Multiple Myeloma

NCT06668792 2025-02-04

FLAMMINGO

Phase 2 Recruiting

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Phase 2 Active not recruiting

Multiple Myeloma

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT06115135 2025-01-16

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma